Multiple Sclerosis

RHB-104 is a proprietary, oral, investigational, antibiotic combination therapy, with intracellular, antimycobacterial and anti- inflammatory properties.

RHB-104 is targeting several indications, including multiple sclerosis, an inflammatory, demyelinating, and neurodegenerative disease of the central nervous system that exhibits characteristics of both infectious and autoimmune pathology.

RHB-104 is a multifaceted drug that in addition to bactericidal properties against intracellular infections, has potentially distinct mechanisms of action that include both anti-inflammation and neuroprotection.

RedHill has successfully completed a Phase 2a proof of concept clinical study of RHB-104 as an add-on therapy to interferon beta-1a in patients with relapsing remitting multiple sclerosis (the CEASE MS study). The study demonstrated positive safety and clinical signals supporting the therapeutic potential of RHB-104 in multiple sclerosis. 

RHB 104